news aktuell GmbH

JP Hospitality acquires tradition-rich vintage hotel in heart of Madonna di Campiglio’s town centre

29.6.2022 10:00:14 CEST | news aktuell GmbH | Pressemelding

Del
Fourth acquisition by Viennese investor group in 2022

Vienna, 28th of June 2022

The JP Hospitality Investors Club has acquired Hotel Milano in Madonna di Campiglio (altitude: 1,600 metres), a property surrounded by the breathtaking mountain scenery of the Brenta Dolomites.

Daniel Jelitzka, founder of JP Immobilien Group and chairman of the Advisory Board at JP Hospitality, explained that the acquisition of Hotel Milano fits into the Investors Club’s strategy very well: “Madonna di Campiglio is a one-of-a-kind ski town in the northern Italian Alps with its own unique charm, and it offers the ideal conditions for a wide range of winter and summer tourist activities. With a refurbished, hip hotel and an attractive range of culinary offerings, we will cover the resilient and very much in demand lifestyle segment here.”

The hotel offers around 50 rooms and is located in the middle of the pedestrian zone in the Alpine village of Madonna di Campiglio, roughly a one-minute walk from the valley chairlift station for the famous World Cup race course. In collaboration with an international operator, the hotel will be renovated and repositioned as a mid to upscale Alpine lifestyle hotel.

“We will give an existing property a modern update with a clear design and develop it into an Alpine lifestyle hotel located in one of Europe’s most attractive Alpine winter and summer tourist destinations,” commented Lukas Euler-Rolle, CEO of JP Hospitality, enthusiastically.

Gebhard Schachermayer, CAM of JP Hospitality, pointed out that “the vintage hotel features an ideal location in the heart of the town centre and has tremendous catch-up potential with modern F&B and wellness offerings.”

Download

www.jpi.at

For enquiries, please contact:

Petra Menasse-Eibensteiner / JP Immobilien

+43 699 126 39 220

petra@menassemenasse.at 

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release

Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.

Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release

Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.

Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release

(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release

Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye